Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 7/20 | 0.69 |
| ▸ | LMNA | P02545 | 1/20 | 0.69 |
| ▸ | THRB | P10828 | 1/20 | 0.69 |
| ▸ | MTOR | P42345 | 1/20 | 0.69 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.69 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.69 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 3/20 | 0.64 |
| ▸ | ST6GAL1 | P15907 | 5/20 | 0.64 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cytarabine 5'-Phosphate SCHEMBL20277485 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL14669262 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL207204 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL284602 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL11217191 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL16189 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL6115643 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL2681941 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL18785109 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 | |
| Cytarabine 5'-Phosphate SCHEMBL29450798 | 1.00 | P2RY2 (0.69) | P2RY2LMNATHRBMTORMDM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230279266-A1 | POLISHING LIQUID COMPOSITION FOR SILICON OXIDE FILMS | KAO CORPORATION (JP) | 2023-09-07 | — | — | US | disclosed |
| US-20170112948-A1 | Inorganic-organic hybrid compound | Karlsruher Institut für Technologie (DE) | 2017-04-27 | — | — | US | disclosed |
| US-20160205924-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | MODERNATX, INC. | 2016-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112948-A1 | Inorganic-organic hybrid compound | SLCO4C1, SLCO2A1, SLCO1A2 | P2RY2 1037/4885LMNA 3032/4885THRB 4145/4885 |
| US-20160205924-A1 | METHODS OF INCREASING THE VIABILITY OR LONGEVITY OF AN ORGAN OR ORGAN EXPLANT | RNGTT, L3MBTL3, RNASE1 | P2RY2 3344/4885LMNA 281/4885THRB 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.